Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Summit Therapeutics is dedicated to discovering, developing and commercializing novel medicines to address unmet medical needs.

Summit Therapeutics’ vision is to become a major player in the development and commercialisation of innovative medicines in areas of unmet medical need.

Summit Therapeutics have achieved several awards, including the Red Herring Europe 100 Top Private Companies Award, the EY Entrepreneur of the Year Award, and the HealthTech and MedTech category in the Deloitte Technology Fast 50 award. They have a strong commitment to patient safety and excellence in R&D that has been recognised by numerous awards.